Investors had grown accustomed to strong results after five consecutive quarterly ‘high quality’ beats. However, its Q1 results did not meet MF consensus, which dents the short-term momentum of the story, in our view. We believe Storytel could reverse the negative sentiment at its 15 May CMD, but remain on the sidelines to see if the high bar from consensus is revised. The valuation remains undemanding, in our opinion, as we forecast adj. EBIT growth of 25% YOY in 2025. We reiterate our HOLD, an...
We expect a solid Q1 report, with likely c11% organic growth as well as good margin progress supporting the 2025 guidance. Based on its footprint, we see minimal effect in case of tariffs on pharmaceuticals, with the biggest risk coming from potential reciprocal ones from Europe. We reiterate our BUY and DKK190 target price.
We continue to see a neutral risk/reward ahead of Storytel’s Q1 results and strategy update in May, as expectations have crept up with recent share price gains. Its step-change in profitability and cash flows is mainly explained by gross-margin expansion, and limited low-hanging fruit remains, in our view. Thus, we see less upside potential for meaningful consensus revisions to propel the stock higher. Valuation is undemanding, as we forecast EPS growth of 32% YOY in 2025. We reiterate our HOLD ...
A director at Alk-Abello A S bought 1,606 shares at 155.680DKK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
While one-off costs took the initial focus (albeit broadly pre-warned), a solid underlying performance in Q4 was anchored in the important European tablet sales, which exceeded expectations. We find the 2025 guidance in line with expectations, but see upside risk to consensus on the top line given strong momentum in tablet sales in Europe. We reiterate our BUY and DKK190 target price.
We expect a strong Q4, with c12% organic revenue growth YOY, but the EBIT margin to be under pressure from well flagged one-offs related to optimisation initiatives and revision of its Chinese plans. We expect the 2025 guidance to be in line with expectations and its long-term strategy announced last year for >10% organic revenue growth and a c25% EBIT margin. We reiterate our BUY and DKK190 target price.
The Q4 results were strong across the board, and a solid gross margin again largely explained the recent profit step change; however, we believe there are few low-hanging fruit left. While we forecast 33% YOY growth in EPS in 2025 and the valuation remains undemanding, we see little likelihood of meaningful consensus revisions providing a catalyst other than multiples expansion, implying a modest risk/return. Storytel plans to unveil new medium-term targets in Q2; we believe they could be conser...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.